Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
26 - Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
from Section II - Botulinum Toxin Therapy
Published online by Cambridge University Press: 31 May 2018
Book contents
- Treatment of Dystonia
- Treatment of Dystonia
- Copyright page
- Contents
- Contributors
- Preface
- 1 Development of the Concept of Dystonia as a Disease, a Syndrome and a Movement Phenomenology
- Section I Basics
- Section II Botulinum Toxin Therapy
- 21 The Global Market for Botulinum Toxin
- 22 Molecular Mechanisms of Botulinum Toxin
- 23 Indirect Central Nervous System Effects of Botulinum Toxin
- 24 Direct Central Nervous System Effects of Botulinum Neurotoxin
- 25 Analgesic Effects of Botulinum Toxins
- 26 Manufacture of Commercial Botulinum Neurotoxins for Human Treatment
- 27 Pharmacology of Botulinum Toxins
- 28 Immunology of Botulinum Toxin Therapy
- 29 Use of Non-A/Non-B Botulinum Toxins
- 30 Clinical Muscular Anatomy for the Botulinum Toxin Injector
- 31 Ultrasound Guidance for Botulinum Toxin Application
- 32 Treatment Algorithms and Injection Schemes for Botulinum Toxin Therapy of Dystonia
- 33 Botulinum Toxin Therapy for Cervical Dystonia
- 34 Botulinum Toxin Therapy for Cranial Dystonia
- 35 Botulinum Toxin Therapy for Spasmodic Dysphonia
- 36 Botulinum Toxin Therapy for Writer’s Cramp and Other Focal Hand Dystonias
- 37 Botulinum Toxin Therapy for Bruxism
- 38 Treatment of Blepharospasm With Eyelid-Opening Apraxia
- 39 Organisation of a Botulinum Toxin Clinic
- Section III Musician’s Dystonia
- Section IV Psychogenic Dystonia
- Section V Treatment of Paediatric Dystonia
- Section VI Rehabilitation of Dystonia
- Section VII Pharmacotherapy for Dystonia
- Section VIII Surgical Treatment of Dystonia
- Section IX Deep Brain Stimulation for Dystonia
- Section X Emerging Therapies for Dystonia
- Section XI Future Trends in Dystonia Therapy
- Book part
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Treatment of Dystonia , pp. 120 - 127Publisher: Cambridge University PressPrint publication year: 2018
References
Borodic, G, Johnson, EA, Goodnough, MC, Schantz, EJ (1996) Botulinum toxin therapy, immunologic resistance, and problems with available materials. Neurology 46: 26–29.CrossRefGoogle ScholarPubMed
Brashear, A (2001) Botulinum toxin type B: a new injectable treatment for cervical dystonia. Expert Opin Invest Drugs 10: 2191–2199.CrossRefGoogle ScholarPubMed
Burgen, ASV, Dickens, F, Zatman, LF (1949) The action of botulinum toxin on the neuro-muscular junction. J Physiol 109: 10–24.Google Scholar
DasGupta, BR (1989) The structure of botulinum neurotoxin. In: Simpson, LL, ed., Botulinum Neurotoxin and Tetanus Toxin. San Diego, ca, Academic Press, pp. 53–67.CrossRefGoogle Scholar
Drachman, DB (1971) Botulinum toxin as a tool for research on the nervous system. In: Simpson, LL, ed., Neuropoisons: Their Pathophysiological Actions. Vol. 1. Poisons of Animal Origin. New York, Plenum Press, pp. 325–347.Google Scholar
Frevert, J (2015) Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 15: 1–9.CrossRefGoogle ScholarPubMed
Geigert, J (2013) The Challenge of CMC Regulatory Compliance for Biopharmaceuticals. New York, Springer-Verlag.CrossRefGoogle Scholar
Hambleton, P, Capel, B, Bailey, N, Heron, N, Crooks, A, Melling, J, Tse, C-K, Dolly, JO (1981) Production, purification and toxoiding of Clostridium botulinum type A toxin. In: Lewis, GE, ed., Biomedical Aspects of Botulism. New York, Academic Press, pp. 247–260.Google Scholar
Hatheway, CL, Johnson, EA (1998) Clostridium: the spore-bearing anaerobes. In: Collier, L, Balows, A, Sussman, M, eds, Topley and Wilson’s Microbiology and Microbial Infections, ninth edition, Vol. 2: Systematic Bacteriology. London, Arnold, pp. 731–782.Google Scholar
Hill, KK, Xie, G, Foley, BT, Smith, TJ (2015) Genetic diversity within the botulinum neurotoxin-producing bacteria and their neurotoxins. Toxicon 107 (Pt A): 2–8.CrossRefGoogle ScholarPubMed
Hutson, RA, Zhou, Y, Johnson, EA, Sugiyama, H, Hatheway, CL (1996) Genetic characterization of Clostridium botulinum type A containing silent B neurotoxin gene sequences. J Biol Chem 271: 10786–10792.CrossRefGoogle ScholarPubMed
Johnson, EA (1999) Clostridial toxins as therapeutic agents: benefits of nature’s most toxic proteins. Ann Rev Microbiol 53: 551–575.CrossRefGoogle ScholarPubMed
Malizio, CJ, Goodnough, MC, Johnson, EA (2000) Purification of Clostridium botulinum type A neurotoxin. In: Holst, O, ed., Bacterial Toxins: Methods and Protocols. New Jersey, Humana Press.Google Scholar
Panjwani, N, O’Keefe, RO, Pickett, A (2008) Biochemical, functional and potency characteristics of type A botulinum toxin in clinical use. The Botulinum J 1: 153–166.Google Scholar
Pickett, A (2014) Botulinum toxin as a clinical product: manufacture and pharmacology. In: Foster, KA, ed., Clinical Applications of Botulinum Neurotoxin. New York, Springer, pp. 7–49.Google Scholar
Rossetto, O, Pirazzini, M, Montecucco, C (2014) Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol 12: 535–549.CrossRefGoogle ScholarPubMed
Sakaguchi, G (1982) Clostridium botulinum toxins. Pharmacol Ther 19: 165–194.CrossRefGoogle ScholarPubMed
Schantz, EJ, Johnson, EA (1992) Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol Rev 56: 80–92.CrossRefGoogle ScholarPubMed
Scott, AB (1981) Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophtthalmol Soc 79: 734–770.Google ScholarPubMed
Scott, AB (1989) Clostridial toxins as therapeutic agents. In: Simpson, LL, ed., Botulinum Neurotoxin and Tetanus Toxin. San Diego, CA, Academic Press, pp. 399–412.CrossRefGoogle Scholar
Scott, AB, Rosenbaum, A, Collins, CC (1973) Pharmacologic weakening of extraocular muscles. Invest Opthamol 12: 924–927.Google ScholarPubMed
Sugiyama, H (1980) Clostridium botulinum neurotoxin. Microbiol Rev 44: 419–448.CrossRefGoogle ScholarPubMed
Wortzman, MS, Pickett, A (2009) The science and manufacturing behind botulinum neurotoxin type A-ABO in clinical use. Aesthet Surg J 29: S34–S42.Google Scholar